- Home
- ASC vs CAPR Comparison
ASC vs CAPR Comparison
Compare ASC & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASC
- CAPR
- Stock Information
- Founded
- ASC 2010
- CAPR 2005
- Country
- ASC Bermuda
- CAPR United States
- Employees
- ASC N/A
- CAPR N/A
- Industry
- ASC Marine Transportation
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASC Consumer Discretionary
- CAPR Health Care
- Exchange
- ASC Nasdaq
- CAPR Nasdaq
- Market Cap
- ASC 511.3M
- CAPR 578.4M
- IPO Year
- ASC 2013
- CAPR N/A
- Fundamental
- Price
- ASC $12.23
- CAPR $13.70
- Analyst Decision
- ASC Buy
- CAPR Strong Buy
- Analyst Count
- ASC 3
- CAPR 7
- Target Price
- ASC $20.00
- CAPR $39.29
- AVG Volume (30 Days)
- ASC 759.6K
- CAPR 1.1M
- Earning Date
- ASC 02-13-2025
- CAPR 02-27-2025
- Dividend Yield
- ASC 8.82%
- CAPR N/A
- EPS Growth
- ASC 6.23
- CAPR N/A
- EPS
- ASC 3.55
- CAPR N/A
- Revenue
- ASC $422,624,000.00
- CAPR $23,228,045.00
- Revenue This Year
- ASC N/A
- CAPR N/A
- Revenue Next Year
- ASC N/A
- CAPR $74.85
- P/E Ratio
- ASC $3.45
- CAPR N/A
- Revenue Growth
- ASC N/A
- CAPR 65.33
- 52 Week Low
- ASC $10.86
- CAPR $3.52
- 52 Week High
- ASC $23.44
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- ASC 47.77
- CAPR 45.79
- Support Level
- ASC $12.83
- CAPR $12.31
- Resistance Level
- ASC $13.85
- CAPR $16.17
- Average True Range (ATR)
- ASC 0.47
- CAPR 0.83
- MACD
- ASC 0.05
- CAPR 0.07
- Stochastic Oscillator
- ASC 24.65
- CAPR 36.01
About ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.